Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry

BACKGROUND: Temsirolimus is a mTOR inhibitor approved for the first-line treatment of advanced or metastatic renal cell carcinoma (a/mRCC) with poor prognosis. In treatment of a/mRCC several prognostic scoring systems are used. We assessed the prognostic value of these scores in a large temsirolimus...

Descripción completa

Detalles Bibliográficos
Autores principales: Boegemann, Martin, Goebell, Peter Jürgen, Woike, Michael, Buncke, Johanna, Schlack, Katrin, Schrader, Andres Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article on Management of Advanced Genitourinary Malignancies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575558/
https://www.ncbi.nlm.nih.gov/pubmed/34804848
http://dx.doi.org/10.21037/tau-20-938

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575558/
https://www.ncbi.nlm.nih.gov/pubmed/34804848
http://dx.doi.org/10.21037/tau-20-938

Ejemplares similares